What is Afynia?
Afynia Laboratories Inc., formerly known as AIMA Laboratories Inc., is a specialized FemTech enterprise founded by reproductive endocrinology experts. The company is dedicated to bridging the significant diagnostic and therapeutic voids in women's health. Its primary focus involves the development of innovative, science-backed products designed to assist individuals suffering from infertility, menstrual pain, and chronic pelvic conditions. By integrating deep scientific research with clinical diagnostic expertise, Afynia is establishing itself as a high-authority entity in the reproductive health market, aiming to improve patient outcomes through precision medicine and targeted diagnostic tools.
How much funding has Afynia raised?
Afynia has raised a total of $6.5M across 2 funding rounds:
Other Financing Round
$1.5M
Angel/Seed
$5M
Other Financing Round (2024): $1.5M with participation from Gaingels, Aventura VC, and SOSV
Angel/Seed (2025): $5M led by Capital Angel Network, Impact America Fund, Bio-Rad, Gaingels, and SOSV
Key Investors in Afynia
SOSV
SOSV is a multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
Gaingels
Gaingels is the leading investment syndicate in support of and representing the LGBTQ community and allies in the venture capital space.
Bio-Rad
Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.
What's next for Afynia?
With the successful closure of this major strategic investment, Afynia is poised to enter a critical phase of clinical validation and product commercialization. The company's strategic roadmap likely involves scaling its research infrastructure and navigating the regulatory pathways necessary to bring its flagship endometriosis diagnostic to market. Given the backing from specialized life science investors and diverse venture syndicates, Afynia is expected to prioritize the expansion of its intellectual property portfolio and the strengthening of its clinical partnerships. This phase of development will be essential for the company to solidify its market position and address the unmet needs of the global FemTech demographic, ultimately driving long-term value for stakeholders and patients alike.
See full Afynia company page
